封面
市場調查報告書
商品編碼
1785223

靜脈曲張治療市場-全球產業規模、佔有率、趨勢、機會和預測(按類型、按組件、按最終用戶、按地區和競爭細分,2020-2030 年)

Varicose Veins Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type, By Component, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年,全球靜脈曲張治療市場規模達14.5億美元,預計2030年將達20.8億美元,預測期內複合年成長率為6.32%。隨著人們對靜脈疾病認知的不斷提高以及對微創手術的需求不斷成長,全球靜脈曲張治療市場正在經歷顯著成長。

市場概覽
預測期 2026-2030
2024年市場規模 14.5億美元
2030年市場規模 20.8億美元
2025-2030 年複合年成長率 6.32%
成長最快的領域 靜脈內消融術
最大的市場 北美洲

例如,根據德國醫療品質與效率研究所的研究估計,大約 20% 的成年人會在一生中的某個階段經歷靜脈曲張。雖然蜘蛛靜脈在老年人中更為常見,但年輕人也可能受到這些靜脈疾病的影響。靜脈曲張是由於瓣膜故障導致靜脈擴張和扭曲而發生的,這種疾病正變得越來越普遍,尤其是在老齡化人口和久坐不動的人群中。隨著越來越多的患者出於美容和健康原因尋求醫療協助,醫療保健提供者正在擴大其提供的有效治療方案。雷射治療、射頻消融和硬化療法的技術進步正在改變治療格局,提供更快的恢復時間、更少的疼痛和最小的疤痕。這些創新使門診治療更容易獲得,對患者更具吸引力,從而促進了市場採用。

關鍵市場促進因素

靜脈曲張和靜脈疾病盛行率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

靜脈內雷射消融術(EVLA)的快速應用

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球靜脈曲張治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依類型(靜脈內消融術、硬化療法、手術結紮和剝離術)
    • 按組件(消融設備、射頻消融設備、雷射消融設備、靜脈閉合產品、其他)
    • 按最終使用者(醫院和診所、門診護理中心、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖
    • 按類型
    • 按組件
    • 按最終用戶
    • 按地區

第6章:北美靜脈曲張治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章:歐洲靜脈曲張治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太靜脈曲張治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章:南美靜脈曲張治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東與非洲靜脈曲張治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 13 章:競爭格局

  • Alma Lasers Limited
  • Medtronic Plc.
  • Boston Scientific Corporation (Lumenis Corporation)
  • Sciton, Inc
  • Merit Medical Systems, Inc.
  • BTG International Limited
  • Energist Limited
  • Teleflex Incorporated
  • AngioDynamics, Inc.
  • El. En SpA Group (Quanta System)

第 14 章:策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 14580

Global Varicose Veins Treatment Market was valued at USD 1.45 billion in 2024 and is expected to reach USD 2.08 billion by 2030 with a CAGR of 6.32% during the forecast period. The global varicose veins treatment market is experiencing significant growth due to increasing awareness of venous disorders and the rising demand for minimally invasive procedures.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.45 Billion
Market Size 2030USD 2.08 Billion
CAGR 2025-20306.32%
Fastest Growing SegmentEndovenous ablation
Largest MarketNorth America

For instance, according to the study from Germany's Institute of Quality and Efficiency in Healthcare estimates that roughly 20% of adults will experience varicose veins at some point in their lives. Although spider veins are more prevalent among the elderly, younger people can also be affected by these venous conditions. Varicose veins, which occur when veins become enlarged and twisted due to faulty valves, are becoming more prevalent, especially among aging populations and individuals with sedentary lifestyles. With more patients seeking medical attention for both cosmetic and health reasons, healthcare providers are expanding their offerings for effective treatment options. Technological advancements in laser therapy, radiofrequency ablation, and sclerotherapy are transforming the treatment landscape, offering quicker recovery times, reduced pain, and minimal scarring. These innovations have made outpatient procedures more accessible and appealing to patients, boosting market adoption.

Key Market Drivers

Rising Prevalence of Varicose Veins and Venous Disorders

The rising prevalence of varicose veins and venous disorders is a major factor driving the growth of the global varicose veins treatment market. Varicose veins are a common condition characterized by swollen, twisted veins that most often occur in the legs due to weak or damaged vein walls and valves. Several contributing factors have led to an increase in cases worldwide. Aging is a primary risk factor, as vein elasticity naturally declines over time, making older adults more susceptible. Hormonal changes, particularly during pregnancy and menopause, also contribute to the weakening of vein walls, increasing the likelihood of varicose vein development, especially among women. Obesity and a sedentary lifestyle are closely linked to venous insufficiency. Excess body weight places additional pressure on leg veins, while prolonged sitting or standing impairs circulation and contributes to valve dysfunction. These lifestyle patterns are increasingly common across both developed and developing nations, resulting in a higher burden of venous disorders. Occupational risk is another concern, with many individuals in professions requiring long hours of standing or sitting-such as healthcare workers, teachers, and office employees-experiencing higher susceptibility.

As awareness of varicose veins has grown, more individuals are seeking medical care not only for physical symptoms such as pain, swelling, and heaviness in the legs but also for cosmetic concerns. Patients are becoming more proactive about managing early signs of venous disorders to prevent complications like chronic venous insufficiency, ulcers, and deep vein thrombosis. This rising demand for diagnosis and intervention is pushing healthcare systems and providers to invest in advanced treatment options. The increasing prevalence across diverse population segments continues to generate significant momentum for innovation and expansion within the varicose veins treatment market, as the need for effective, accessible, and minimally invasive solutions becomes more urgent.

Key Market Challenges

High Treatment Costs

High treatment costs remain one of the major challenges impacting the global varicose veins treatment market. Although minimally invasive procedures have transformed care by offering better outcomes and faster recovery, they often come at a premium. Techniques such as endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and ultrasound-guided foam sclerotherapy require advanced medical equipment, skilled professionals, and precise imaging systems. These elements drive up the overall cost of diagnosis and treatment, making it less accessible for a large segment of the population, especially in low- and middle-income countries. The financial burden is compounded by the fact that varicose vein treatments are frequently categorized as elective or cosmetic in nature, which limits insurance coverage or reimbursement eligibility. Many insurance providers do not cover these procedures unless there is documented evidence of medical necessity, such as chronic pain, ulceration, or venous insufficiency. As a result, out-of-pocket expenses can be substantial, deterring patients from seeking timely care.

In public healthcare systems, cost constraints can lead to long wait times and limited access to specialized care, particularly when prioritization is given to life-threatening conditions. Private healthcare facilities, while offering advanced treatments with minimal delays, often remain financially out of reach for a large portion of the population. This cost-related disparity results in delayed intervention, increased complication rates, and higher long-term healthcare expenses. Healthcare providers and manufacturers are working to address this challenge by introducing cost-effective technologies and expanding the use of outpatient treatment settings, which can help reduce hospital overhead. However, until there is broader access to affordable treatment and improved insurance support, high costs will continue to be a barrier for many patients. This challenge underscores the need for strategic pricing, wider public healthcare funding, and awareness around the long-term benefits of early varicose vein treatment.

Key Market Trends

Rapid Adoption of Endovenous Laser Ablation (EVLA)

The rapid adoption of endovenous laser ablation (EVLA) is significantly transforming the global varicose veins treatment market. EVLA has emerged as a preferred treatment method for varicose veins due to its minimally invasive nature, high success rate, and faster recovery compared to traditional surgical procedures like vein stripping. Patients and physicians alike are drawn to its clinical advantages, including reduced postoperative pain, minimal scarring, and a low risk of complications. These benefits align well with the growing demand for outpatient procedures that offer convenience without compromising effectiveness. EVLA uses targeted laser energy to seal faulty veins, causing them to collapse and eventually be absorbed by the body. The procedure is typically performed under local anesthesia, allowing patients to return to daily activities within a short period. This efficiency has made EVLA a go-to option for individuals seeking both functional and cosmetic relief from varicose veins. As awareness spreads about its effectiveness and safety profile, healthcare providers are increasingly incorporating EVLA into their service offerings. The availability of advanced laser systems with improved wavelength control, cooling technologies, and fiber-optic precision is further accelerating the use of EVLA in clinical practice. Medical device companies are actively investing in research and development to enhance system performance and user experience, ensuring better patient outcomes and procedure efficiency. Clinics and hospitals are adopting these technologies to stay competitive and meet patient expectations for modern, less invasive solutions. With insurance providers beginning to recognize the long-term cost savings of minimally invasive treatments like EVLA, reimbursement support is also gradually improving in some regions. This shift is helping to make the procedure more accessible. As the market continues to favor less invasive approaches, the role of EVLA is expected to grow, solidifying its place as a key driver of innovation and expansion in varicose vein management.

Key Market Players

  • Alma Lasers Limited
  • Medtronic Plc.
  • Boston Scientific Corporation (Lumenis Corporation)
  • Sciton, Inc
  • Merit Medical Systems, Inc.
  • BTG International Limited
  • Energist Limited
  • Teleflex Incorporated
  • AngioDynamics, Inc.
  • El. En SpA Group (Quanta System)

Report Scope:

In this report, the Global Varicose Veins Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Varicose Veins Treatment Market, By Type:

  • Endovenous Ablation
  • Sclerotherapy
  • Surgical Ligation & Stripping

Varicose Veins Treatment Market, By Component:

  • Ablation Devices
  • Radiofrequency Ablation Devices
  • Laser Ablation Devices
  • Venous Closure Products
  • Others

Varicose Veins Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Varicose Veins Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Varicose Veins Treatment Market.

Available Customizations:

Global Varicose Veins Treatment Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Varicose Veins Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Endovenous Ablation, Sclerotherapy, Surgical Ligation & Stripping)
    • 5.2.2. By Component (Ablation Devices, Radiofrequency Ablation Devices, Laser Ablation Devices, Venous Closure Products, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Component
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Varicose Veins Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Component
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Varicose Veins Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Component
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Varicose Veins Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Component
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Varicose Veins Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Component
        • 6.3.3.2.3. By End User

7. Europe Varicose Veins Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Component
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Varicose Veins Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Component
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Varicose Veins Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Component
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Varicose Veins Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Component
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Varicose Veins Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Component
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Varicose Veins Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Component
        • 7.3.5.2.3. By End User

8. Asia-Pacific Varicose Veins Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Component
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Varicose Veins Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Component
        • 8.3.1.2.3. By End User
    • 8.3.2. India Varicose Veins Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Component
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Varicose Veins Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Component
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Varicose Veins Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Component
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Varicose Veins Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Component
        • 8.3.5.2.3. By End User

9. South America Varicose Veins Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Component
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Varicose Veins Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Component
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Varicose Veins Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Component
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Varicose Veins Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Component
        • 9.3.3.2.3. By End User

10. Middle East and Africa Varicose Veins Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Component
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Varicose Veins Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Component
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Varicose Veins Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Component
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Varicose Veins Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Component
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Alma Lasers Limited
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Recent Developments
    • 13.1.6. SWOT Analysis
  • 13.2. Medtronic Plc.
  • 13.3. Boston Scientific Corporation (Lumenis Corporation)
  • 13.4. Sciton, Inc
  • 13.5. Merit Medical Systems, Inc.
  • 13.6. BTG International Limited
  • 13.7. Energist Limited
  • 13.8. Teleflex Incorporated
  • 13.9. AngioDynamics, Inc.
  • 13.10. El. En SpA Group (Quanta System)

14. Strategic Recommendations

15. About Us & Disclaimer